Wide Ranks

ENGN

enGene Holdings Inc.

8.61

Top Statistics
Market Cap 438 M Forward PE -5.48 Revenue Growth 0.00 %
Current Ratio 19.52 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.69 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 257 M Total Cash Per Share 5.83 Total Debt 24 M
Total Debt To Equity 10.79 Current Ratio 19.52 Book Value Per Share 5.21
All Measures
Short Ratio 574.00 % Message Board Id finmb_9516520 Shares Short Prior Month 813007
Return On Equity -1.23 City Saint-Laurent Uuid f9f4e2ed-4011-3f93-916a-f8a188a8b358
Previous Close 8.60 First Trade Date Epoch Utc 1 B Book Value 5.21
Beta -0.7570 Total Debt 24 M Volume 79977
Price To Book 1.65 Fifty Two Week Low 4.42 Total Cash Per Share 5.83
Shares Short Previous Month Date 1 B Target Median Price 30.00 Max Age 86400
Recommendation Mean 1.38 Sand P52 Week Change 0.3133 Target Mean Price 28.12
Net Income To Common -123436000 Short Percent Of Float 0.0200 Implied Shares Outstanding 50 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 45090
Average Volume10days 45090 Total Cash 257 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1361 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 8.60 Target Low Price 16.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 7.84 Open 9.01
Free Cashflow -23581124 State QC Dividend Yield 0.00 %
Return On Assets -0.2207 Time Zone Short Name EST Trailing Eps -2.79
Day Low 8.20 Address1 7171 Rue Frederick Banting Shares Outstanding 50 M
Price Hint 2 Target High Price 40.00 Website https://www.engene.com
52 Week Change 0.1240 Average Volume 165389 Forward Eps -1.69
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1916.50 %
Is_sp_500 False Regular Market Day High 9.15 Profit Margins 0.00 %
Debt To Equity 10.79 Fifty Two Week High 18.40 Day High 9.15
Shares Short 769437 Regular Market Open 9.01 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0151
Operating Cashflow -35489000 Currency USD Time Zone Full Name America/New_York
Market Cap 438 M Is_nasdaq_100 False Zip H4S 1Z9
Quote Type EQUITY Industry Biotechnology Long Name enGene Holdings Inc.
Regular Market Day Low 8.20 Held Percent Institutions 0.8323 Current Price 8.61
Enterprise To Ebitda -2.69 Financial Currency USD Current Ratio 19.52
Industry Disp Biotechnology Number Of Analyst Opinions 8 Country Canada
Float Shares 16 M Two Hundred Day Average 10.68 Enterprise Value 147 M
Forward PE -5.48 Regular Market Volume 79977 Ebitda -54995000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.

Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

The company was founded in 2023 and is based in Saint-Laurent, Canada.